Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
RTNominal down32.300 -0.450 (-1.374%)

29/08/2019 14:04

{I-bank focus}Goldman cuts Fosun Pharma (02196) to HK$28.8

[ET Net News Agency, 29 August 2019] Goldman Sachs lowered its target price for
Shanghai Fosun Pharmaceutical (02196) to HK$28.8 from HK$35.47 and maintained its "buy"
rating, given upside potential from newly launched drugs.
The research house said Fosun Pharma's 2Q sales of Rmb7.4bn beat. Gross margin continued
to expand, with revenue mix shifts to pharma, which was also undergoing gradual product
mix upgrade, partially offset by higher SG&A with a new commercial team for biosimilars
and a US sales team. But earnings of Rmb804m missed as widening loss from business
incubators in the US/EU led to higher effective tax/minorities.
Goldman revised up its 2019 EPS forecast by 26.8% to factor in primarily a one-off gain
from the disposal of United Family Hospital in 4Q (Rmb1.6bn, based on company filings,
with the timing of the gain to be booked announced during the 2Q results conference call).

Remark: Real time quote last updated: 27/11/2020 17:59
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2020 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.